Regulation of blood viscosity in disease prevention and treatment by Gan Chen et al.
   
 
© The Author(s) 2012. This article is published with open access at Springerlink.com csb.scichina.com   www.springer.com/scp 
                      
*Corresponding author (email: zhouhtt@yahoo.com.cn) 
Review 
Preclinical Medicine June 2012  Vol.57  No.16: 19461952 
 doi: 10.1007/s11434-012-5165-4  
Regulation of blood viscosity in disease prevention and treatment 
CHEN Gan1, ZHAO Lian1, LIU YaoWen3, LIAO FuLong2, HAN Dong2 & ZHOU Hong1* 
1 Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China; 
2 National Center for Nanoscience and Technology, Beijing 100080, China; 
3 Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China 
Received May 31, 2011; accepted October 19, 2011 
 
Blood viscosity plays an important role in maintaining vascular homeostasis. Under normal physiological conditions, blood vis-
cosity is kept at a relatively stable level by a variety of regulatory mechanisms. However, under pathological conditions, disorders 
in these regulatory mechanisms mediated by endothelial cell dysfunction result in the pathogenesis and development of certain 
diseases, such as cardio-cerebrovascular diseases, diabetes mellitus, and hemorrhagic shock. Therefore, monitoring and regulating 
blood viscosity are important for the diagnosis, treatment, and prognosis of disease. This article reviews the role of blood viscosity 
regulation and its importance in disease prevention and treatment. 
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Viscosity, a basal parameter in rheology, is a major deter-
minant of the shear stress imparted by blood flow, and plays 
an important role in maintaining vascular homeostasis. 
Blood viscosity is mainly determined by hematocrit levels, 
plasma viscosity, and the deformability and aggregation of 
red blood cells (RBCs). Blood viscosity varies under normal 
physiological conditions due to differences in heredity, sex, 
and geography. Under pathological conditions, changes in 
blood viscosity usually correlate with endothelial cell dys-
function and changes in the shear stress imparted by blood 
flow, which can damage the circulatory system and related 
tissues and organs. Abnormal blood viscosity plays an im-
portant role in the development of cardio-cerebrovascular 
disease, diabetes, hemorrhagic shock, and renal disease. 
When treating these diseases, much attention is paid to the 
regulation of blood viscosity, which is pivotal to successful 
treatment and avoiding undesirable syndromes. Since the 
1970s, researchers have paid greater attention to the role of 
hemorheological parameters, including blood viscosity, in 
the diagnosis and treatment of diseases [1]. In the 1980s, the 
relationship between hemorheology and disease was inten-
sively investigated and several monographs were published 
[2,3]. Therefore, this article will review recent progress re-
garding the manipulation of blood viscosity for disease pre-
vention and treatment.  
1  Blood viscosity under physiological conditions 
Within the physiological range of shear rates, blood viscos-
ity is primarily determined by hematocrit levels and plasma 
viscosity [4]. The deformability and aggregation of eryth-
rocytes and the interaction between blood cells are also im-
portant contributing factors. The viscosity of plasma, which 
has similar properties to those of a Newtonian fluid, is de-
termined mainly by the concentration of plasma proteins, 
but the erythrocyte deformability and aggregation vary with 
different blood shear rates. Therefore, blood has the proper-
ties of a pseudoplastic non-Newtonian fluid. In addition to 
plasma and hematocrit, erythrocyte deformability at high 
shear rates (>200 s1) is a major determinant of blood vis-
cosity. At low shear rates, blood viscosity is affected by 
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deformability and aggregation of erythrocytes and by plate-
let aggregation [5,6]. 
Epidemiological studies show that blood viscosity is af-
fected by many factors. A study conducted in apparently 
normal adults by De Simone et al. [7] found that cholesterol 
and triglyceride levels were positively related to blood vis-
cosity; obesity, high sodium intake and aging also increased 
blood viscosity. Mental stress may also induce the decrease 
in erythrocyte deformability and an acute elevation in hem-
atocrit levels [6,8,9]. Blood viscosity is also influenced by 
gender. Men have a significantly higher blood viscosity 
than women due to differences in hematocrit and the de-
formability and aggregation of erythrocytes [7,8,10]. Geo-
graphical factors also affect blood viscosity. Compared with 
low-altitude residents, high altitude-residents have higher 
levels of hematocrit, blood viscosity [11–13], blood flow, 
and circulating nitric oxide (NO) products [14]. A study by 
Cheng et al. [15] indicates that, although hematocrit is 
higher among high-altitude residents, compensatory regula-
tion can prevent excessive increases in blood viscosity via 
increased erythrocyte deformability and decreased erythro-
cyte aggregation. Martini et al. [16] suggest that high alti-
tudes cause increased hematocrit levels and, therefore, in-
creased blood viscosity, which results in increased shear 
stress on the endothelium; this, in turn, causes the release of 
stress-mediated vasodilators, leading to a reduction in blood 
pressure. This may be one of the explanations for the low 
mortality from coronary heart disease and stroke observed 
in high altitude residents [17]. 
Under normal physiological conditions, variations in 
blood viscosity directly affect the endothelium, which then 
regulates blood viscosity and blood vessel diameter by releas-
ing vasoactive factors to keep the vascular wall shear stress 
relatively stable. Because of these endothelium-dependent 
regulatory mechanisms, increased blood viscosity does not 
result in increases vascular resistance. In a large-scale epi-
demiological study, De Simone et al. [18] found that blood 
viscosity was negatively related to pulse pressure in appar-
ently normal adults. A study by Salazar Vázquez et al. 
[19,20] showed that mean arterial blood pressure (MAP), 
which reflects peripheral vascular resistance, was negatively 
correlated with blood viscosity in healthy children and 
premenopausal women, but this was not significant. However, 
some research suggests that, hematocrit levels and blood vis-
cosity in normal adults do not correlate with MAP [21].  
2  Abnormalities in blood viscosity and disease 
Abnormal changes in blood viscosity play an important role 
in the pathogenesis and development of many diseases, in-
cluding cardio-cerebrovascular diseases, diabetes mellitus, 
and hemorrhagic shock. Abnormal changes in blood viscos-
ity and endothelial dysfunction promote each other, forming 
a vicious circle. Endothelial cell dysfunction, a key link in 
the pathogenesis of many diseases, is associated with im-
balances in the production and release of vasoactive factors, 
such as vasoconstrictors and vasodilators, pro-coagulant and 
anti-coagulant factors, and inhibitors and promoters of pro-
liferation [22].  
2.1  Abnormalities in blood viscosity and cardio-  
cerebrovascular diseases 
Increased blood viscosity is associated with cardio-cerebro-      
vascular diseases. In a 5-year follow-up study, Lowe et al. 
[23] found that blood viscosity and plasma viscosity were 
significantly higher in patients who experienced cardiovas-
cular events than in those who did not, and that was because 
of increases in fibrinogen concentration and hematocrit. In a 
similar study, Lee et al. [24] showed that increased blood 
viscosity was associated with the early stages of atheroscle-
rosis. In addition, hyperviscosity may play a role in the oc-
currence of cerebral ischemic complications in patients with 
atrial fibrillation (AF). AF patients who had experienced 
previous cerebral ischemic events had a higher blood vis-
cosity than AF patients who had not experienced such events 
[25].  
Abnormal increases in blood viscosity are associated 
with the development and prognosis of cardio-cerebrovas-     
cular diseases. Increasing hematocrit, abnormal increases in 
fibrinogen concentration, and blood viscosity can all make 
cardio-cerebrovascular diseases worse and increase the long 
term risk of mortality [26,27]. Cecchi et al. [28] found that 
blood viscosity was independently and positively associated 
with infarct size. It is possible that increased blood viscosity 
may contribute to a lack of myocardial perfusion, which 
may then result in an increased infarct size. Malinova et al. 
[29] undertook a 7-year follow-up study in patients with 
ischemic heart disease and suggested that blood viscosity 
and blood flow change with the severity of coronary artery 
disease. In hypertensive men, increased blood viscosity at 
low shear rates is a predictor of cardiovascular events, includ-
ing acute myocardial infarction, unstable angina, or stroke [30]. 
In cardio-cerebrovascular diseases, abnormal increases in 
blood viscosity caused by factors such as an increase in ox-
ygen/nitrogen free radicals, fibrinogen, and oxidized low 
density lipoprotein will not only increase platelet adhesion, 
but also alter vascular wall shear stress. This leads to endo-
thelial dysfunction, increased inflammation, and hypertro-
phy of smooth muscle cells [31], as well as vascular steno-
sis and insufficient blood flow, which can lead to myocardi-
al infarction and stroke. 
2.2  Abnormalities in blood viscosity associated with 
diabetes mellitus 
Increased blood viscosity is closely related to the occurrence 
and development of diabetes mellitus. Insulin resistance and 
hyperinsulinemia predispose to diabetes mellitus. Increased 
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blood viscosity will, in turn, impair blood flow within the 
tissues and limit the delivery of insulin, glucose, and oxy-
gen to metabolically active tissue [32], ultimately resulting 
in increased insulin resistance [33]. Hyperinsulinemic obese 
female patients show significantly higher plasma viscosities 
than normoinsulinemic patients [34]. Increased blood vis-
cosity in patients with diabetes mellitus is an important fac-
tor that contributes to diabetic macrovascular complications 
[19,35,36]. Blood viscosity in diabetic patients is also posi-
tively correlated with the severity of retinopathy [37,38]. 
Diabetic patients with retinopathy show higher blood vis-
cosity than diabetics without retinopathy at both high and 
low shear rates [37]. However, another study came to the 
opposite conclusion [39]. Blood viscosity in diabetic pa-
tients who have experienced complications, such as micro-
albuminuria and nephropathy, is also higher than that in 
patients without such complications [40,41]. Measurements 
of blood viscosity at low shear rates in diabetic patients 
have prognostic value. Compared with those who were ei-
ther asymptomatic or had mild peripheral vascular disease, 
patients with critical limb ischemia showed higher blood 
viscosity and RBC aggregation at low shear rates [42].  
Diabetes mellitus is accompanied by decreased produc-
tion of the vasodilators, NO, and prostacyclin, and increased 
formation of vasoconstrictor eicosanoids [43], leading to 
increased peripheral vascular resistance and abnormal blood 
pressure. This is due to impairment of endothelial vasodila-
tor mechanisms. Salazar Vázquez et al. [21] found a corre-
lation between MAP and hematocrit in patients with a pre-
vious diagnosis of type 2 diabetes. MAP levels decrease 
significantly as hematocrit levels increase within the low 
hematocrit range (<43%), but increase as hematocrit levels 
increase within the high hematocrit range (>43%). Never-
theless, blood viscosity in children with type 1 diabetes is 
positively correlated with MAP, indicating endothelial dys-
function [19].  
Many factors contribute to increased blood viscosity in 
diabetic patients. First, increased glucose causes endothelial 
dysfunction and, therefore, disorders in the feedback mech-
anisms that regulate blood viscosity. Second, high glucose 
levels increase the generation of active oxygen species in 
erythrocytes and endothelial cells, leading to reduced RBC 
deformability and increased blood viscosity. Third, in-
creased RBC aggregation [44] and fibrinogen levels also 
contribute to increased blood viscosity in diabetic patients. 
Microcirculatory disturbances caused by abnormal changes 
in blood viscosity may worsen the complications associated 
with diabetes mellitus [45,46].  
2.3  Abnormalities in blood viscosity associated with 
other diseases 
Increased blood viscosity is also observed in other diseases. 
Plasma viscosity, fibrinogen concentration, and RBC ag-
gregation in renal transplant recipients are all significantly 
higher than those in control subjects [47]. Elevated blood 
viscosity in patients with systemic lupus erythematosus may 
be associated with atherothrombotic disease [48]. In addi-
tion, increased blood viscosity is an important factor that 
impacts upon prognosis [49]. As a marker of vasculopathy, 
increased blood viscosity may accelerate disease progres-
sion in Alzheimer’s disease patients by worsening vascu-
lopathy [50]. 
In some diseases, such as chronic anemia and liver dis-
ease, plasma and blood viscosity show a long term decline 
because of low concentration of plasma proteins rather than 
an abnormal increase in blood viscosity [51–53], leading to 
disorders in endothelial shear response mechanisms. This 
may also occur in hemoglobin or RBC diseases [54]. During 
the early stage of severe hemorrhagic shock, a sharp decline 
plasma and blood viscosity occurs resulting from the loss of 
RBCs and plasma proteins [55]. With respect to the micro-
circulation, a rapid decrease in arteriolar blood flow and 
functional capillary density during hemorrhagic shock may 
give rise to microcirculatory disturbances [56,57]. 
3  Regulation of blood viscosity and treatment 
of disease 
As previously mentioned, abnormal changes in blood vis-
cosity are closely related to the pathogenesis and develop-
ment of many diseases. There is growing evidence to sug-
gest that regulation of blood viscosity is beneficial for dis-
ease treatment. Hemodilution can be used to treat diseases 
resulting from abnormal increases in blood viscosity. How-
ever, under a severe decrease in blood viscosity, e.g. hem-
orrhagic shock and extreme hemodilution, the appropriate 
increase in blood viscosity can maintain the shear stress on 
endothelium and maintain vasodilatation, thereby improve 
microcirculation and increase cardiac output [58]. 
3.1  Treatments that reduce blood viscosity 
For diseases associated with abnormal increases in blood 
viscosity, such as cardio-cerebrovascular diseases and dia-
betes mellitus, two methods are currently used to reduce 
viscosity: direct and indirect. Direct methods include plas-
ma exchange, phlebotomy, and rheopheresis. Plasma ex-
change uses plasma substitutes to replace plasma to reduce 
blood viscosity without affecting the packed cell volume. In 
the short term, it reduces blood viscosity, the concentration 
of fibrinogen, and the levels of triglycerides and cholesterol, 
and improves local blood flow [59,60]. Phlebotomy, which 
is used to treat patients with polycythemia vera and hemo-
chromatosis, reduces hematocrit levels, and plasma and 
blood viscosity via controlled bleeding [61,62]. The combi-
nation of phlebotomy and fluid therapy has been used to 
treat diseases such as ischemic stroke and myocardial in-
farction. Strand et al. [63] used phlebotomy and repeated 
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low-molecular weight dextran infusions to treat the early 
phase of ischemic stroke. During the 3-month follow-up, the 
treatment significantly reduced blood viscosity and im-
proved the overall clinical outcome of patients. Rheopheresis 
therapy improves hemorheological parameters by reducing 
fibrinogen levels, low-density lipoprotein cholesterol, and 
alpha-2-macroglobulin and improves the treatment of mi-
crovascular diseases, and relieves the symptoms of age- 
related macular degeneration and peripheral arterial occlu-
sive disease [64]. 
Indirect therapy reduces blood viscosity by regulating the 
factors that influence blood viscosity, such as erythrocytes, 
platelets, and endothelial cells. For example, antioxidant 
therapy uses vitamins E and C to reduce oxidative stress in 
vivo, increase RBC deformability, improve endothelial dys-
function, and lower blood viscosity [65–67]. In a 6-month 
follow-up study, Galduroz et al. [10] found that the extract 
of Ginkgo biloba significantly reduced blood viscosity. Ni-
troglycerin can also reduce blood viscosity, the decrease 
being associated with an increase in myocardial blood flow 
and a decrease in vascular resistance [68]. In addition, the 
essence of stimulating the circulation to end stasis in Chi-
nese Medicine is similar to reducing blood viscosity to im-
prove microcirculation. Traditional Chinese medicines, such 
as Salvia miltiorrhiza Bunge and Ligusticum chuanxiong 
Hort, effectively regulate blood viscosity by protecting the 
endothelium and inhibiting platelet aggregation [69–73]. 
3.2  Treatments that increase blood viscosity 
Blood viscosity shall be increased moderately when treating 
diseases that extremely reduce viscosity. Transfusion is 
commonly used to restore blood volume and improve the 
delivery of oxygen and nutrients. Recent studies interpreted 
the effects of transfusion in terms of maintaining blood vis-
cosity. The studies concluded that transfusion works by 
maintaining viscosity and restoring oxygen-carrying capac-
ity. Transfusion restores blood viscosity, and maintains the 
shear stress on the endothelium and microvascular perfusion 
such that oxygen delivery and removal of metabolites can 
be maintained [58,74–76]. Martini et al. [77] studied ex-
change transfusions of homologous packed red blood cells 
using the awake hamster window chamber model, and ob-
served a moderate elevation of hematocrit (10% above 
baseline), which causing an increased cardiac index, in-
creased oxygen transport and consumption, and a reduction 
in total peripheral vascular resistance. 
Maintenance of blood viscosity should also be taken into 
consideration when developing blood substitutes. Research-
ers found that some hemoglobin-based oxygen carriers 
caused transient systemic hypertension [78,79] and reduced 
cardiac output [80]. This is because large infusions of blood 
substitutes lower blood viscosity and the shear stress on the 
endothelium, which down-regulates the production of vaso-
dilators by endothelial cells, causing vasoconstriction and 
increasing total peripheral vascular resistance [81]. In the 
hemorrhagic shock model, viscous blood substitutes limit 
vasoconstriction [82,83] and improve functional capillary 
density and oxygen content. 
Maintenance of plasma viscosity is critically important 
when rapid infusion of erythrocytes and increased blood 
viscosity cannot be performed. Tsai et al. [84,85] showed 
that the use of high viscosity plasma expanders during ex-
treme hemodilution could maintain functional capillary 
density and significantly improve capillary perfusion. The 
researchers concluded that increased production of vasodi-
lators by the endothelium (e.g. NO) might be the major 
reason for improvements in the microcirculation. Using the 
severe experimental hemorrhagic shock model based on the 
infusion of hypertonic saline, Golden Syrian Hamsters were 
randomly infused with Hextend (6% Hetastarch in lactated 
electrolyte solution, 4 mPa s) or viscosity-enhanced Hex-
tend (Hextend + 0.4% alginate, 8 mPa s). Resuscitation with 
Hextend resulted in higher MAP, but viscosity-enhanced 
Hextend showed better results in terms of improved func-
tional capillary density, microvascular perfusion, and the 
restoration of acid-base balance [86]. 
4  Regulation of blood viscosity 
Although blood viscosity plays an important role in disease 
prevention and treatment, research into the mechanisms that 
regulate blood viscosity is still lacking. Previous studies 
show that the endothelium plays a key role in regulating 
blood viscosity. Endothelium, as both the sensor and effec-
tor of blood viscosity, not only is regulated by blood viscos-
ity [87], but also plays a vital role in the feedback regulation 
mechanisms that control it. The effects of blood viscosity on 
an organism depend on endothelial cell function. Under 
normal physiological conditions, increased blood viscosity 
leads to increased vascular wall shear stress and increased 
production of endothelial-derived relaxing factors, such as 
NO and prostacyclin. These vasoactive substances not only 
cause vasodilatation and, therefore, lower MAP, but also 
reduce blood viscosity by improving RBC deformability, 
thereby suppressing RBC aggregation and platelet aggrega-
tion and adhesion [88–90]. Under pathological conditions, 
many harmful factors, such as mental stress, inflammation 
[27] and high glucose levels, result in increased production 
of reactive oxygen species, fibrinogen, immunoglobulins, 
and hematocrit, which lead to abnormally increased blood 
viscosity. Furthermore, they may both directly and indirect-
ly cause endothelial dysfunction and feedback regulation 
mechanism disorders. Therefore, abnormal changes in blood 
viscosity and endothelial dysfunction promote each other 
and form a vicious circle. 
Blood viscosity is closely related to endothelial cell func-
tion. Malek et al. [91] found that a constant, high level of 
shear stress which generated by the flow and viscosity could 
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suppress the expression of endothelin-1 in bovine aortic 
endothelial cells. Koller et al. [92] varied the viscosity of 
the perfusate in isolated arterioles from the cremaster mus-
cle by adding dextran, and found that, at a constant flow 
rate, increases in the viscosity of the perfusate caused grad-
ual vasodilation. Viscosity-induced dilation was eliminated 
by removing the endothelium from the arterioles, confirming 
that viscosity-induced dilation is endothelium-dependent. 
They concluded that increased perfusate viscosity increased 
shear stress and, thus, induced prostacyclin release by the 
endothelium, resulting in vasodilation. Using the severe 
hemodilution model, Bertuglia [93] found that hyperviscous 
infusions preserved both the endothelium and capillary per-
fusion.  
As mentioned previously, viscosity can affect endothelial 
cell function by altering shear stress. Furthermore, substrate 
stiffness and micro- and nano-structural surfaces can directly 
modulate cell shape, stiffness, gene expression, and adhe-
sion molecule distribution [94–96]. It is interesting to spec-
ulate whether blood viscosity, as one determinant of the 
viscoelasticity of the material that contacts the endothelium, 
may modulate endothelial cell shape, stiffness, gene expres-
sion, adhesion molecule distribution and, therefore, overall 
health status, in addition to directly affecting endothelial 
cells through shear stress. This would constitute an im-
portant additional endothelium-dependent regulatory mecha-
nism of blood viscosity and needs further study. 
5  Conclusions and expectations 
Blood viscosity is an important parameter to be considered 
during drug evaluation and research into their mechanisms 
of action as it correlates closely with the pathogenesis, de-
velopment, and prognosis of cardio-cerebrovascular diseas-
es, diabetes and other diseases. More interest is now being 
paid to treatments that manipulate blood viscosity. However, 
the bio-effectiveness of viscosity is sometimes overlooked 
in the clinic. The role of hemorheology in the pathogenesis, 
development, and prognosis of disease needs more attention. 
Future investigations should include the following: (1) The 
relationship between hemorheological parameters and the 
correlation between abnormal blood viscosity and endothe-
lial cell dysfunction, such as blood viscosity, and the path-
ogenesis, development and prognosis of diseases; (2) the 
benefits of treatments that control blood viscosity at differ-
ent stages of disease; and (3) the correlations between hem-
orheological parameters and other clinical parameters. A 
general system of diagnosis and monitoring of the effec-
tiveness of treatments should also be established. 
Research on blood viscosity has facilitated the develop-
ment of Biomechanopharmacology [97], a new borderline 
discipline that considers the effect of pharmacological in-
terventions on biomechanical factors and the biomechanical 
influence of pharmacokinetics and pharmacodynamics. Me-
chanical impacts on endothelial cell functions are an im-
portant concern of Biomechanopharmacology. Shear stress 
results from flow flux and hydro-viscosity, and regulates 
endothelial cell structure and function; however, the rela-
tionship between flow flux and hydro-viscosity has not been 
comprehensively investigated. Many studies merely focus 
on changes in shear stress caused by altering the flow flux 
without considering hydro-viscosity, which is also a major 
determinant of shear stress [98]. Further intensive studies on 
blood viscosity will promote the development of Biomech-
anopharmacology.  
Studies of the pathogenesis of hemorrhagic shock and 
strategies for resuscitation have identified changes in hem-
orheology during the early stages of hemorrhagic shock [99]. 
Different plasma volume expanders cause different changes 
in blood viscosity and the rheological parameters of RBCs, 
which further affects perfusion of the microcirculation 
[100,101]. In future, we intend to establish both in vitro and 
in vivo research systems to investigate the mechanisms that 
regulate blood and plasma viscosity. The influence of blood 
viscosity on the mechano-properties of endothelial cells will 
be one focus of our future studies. 
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